Cargando…

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013

Detalles Bibliográficos
Autores principales:	Schernthaner, Guntram, Currie, Craig J., Schernthaner, Gerit-Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Diabetes Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920795/ https://www.ncbi.nlm.nih.gov/pubmed/23882041 http://dx.doi.org/10.2337/dcS13-2031

Ejemplares similares

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010
por: Schernthaner, Guntram, et al.
Publicado: (2011)

Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control
por: Höbaus, Clemens, et al.
Publicado: (2020)

Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery
por: Herz, Carsten T., et al.
Publicado: (2021)

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)
por: Saely, Christoph H., et al.
Publicado: (2023)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

Fetuin-A Levels Are Increased in Patients With Type 2 Diabetes and Peripheral Arterial Disease
por: Lorant, David Peter, et al.
Publicado: (2011)

How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment
por: Gallwitz, Baptist, et al.
Publicado: (2013)

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
por: Schernthaner, Guntram
Publicado: (2021)

Endothelial Progenitor Cells Are Related to Glycemic Control in Children With Type 1 Diabetes Over Time
por: Hörtenhuber, Thomas, et al.
Publicado: (2013)

Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
por: Schernthaner, Guntram
Publicado: (2021)

Renal Function but Not Asymmetric Dimethylarginine Is Independently Associated with Retinopathy in Type 2 Diabetes
por: Krzyzanowska, Katarzyna, et al.
Publicado: (2011)

YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease
por: Schernthaner, Gerit-Holger, et al.
Publicado: (2016)

Do we still need supertrees?
por: Haeseler, Arndt von
Publicado: (2012)

Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes
por: Burant, Charles F.
Publicado: (2013)

Is Physical Exercise a Core Therapeutical Element for Most Patients With Type 2 Diabetes?
por: De Feo, Pierpaolo, et al.
Publicado: (2013)

Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes
por: Zierfuss, Bernhard, et al.
Publicado: (2019)

To the editor regarding article “Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study”
por: Mayer, Florian J., et al.
Publicado: (2018)

Angiogenin—A Proposed Biomarker for Cardiovascular Disease—Is Not Associated With Long-Term Survival in Patients With Peripheral Artery Disease
por: Höbaus, Clemens, et al.
Publicado: (2021)

Vascular peroxidase 1 is independently associated with worse kidney function in patients with peripheral artery disease
por: Costas, Lavinia, et al.
Publicado: (2020)

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
por: Eldor, Roy, et al.
Publicado: (2013)

The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
por: Czupryniak, Leszek, et al.
Publicado: (2021)

NT-proBNP as a surrogate for unknown heart failure and its predictive power for peripheral artery disease outcome and phenotype
por: Zierfuss, Bernhard, et al.
Publicado: (2023)

Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
por: Schernthaner, G., et al.
Publicado: (2016)

Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes
por: Höbaus, Clemens, et al.
Publicado: (2021)

Why do we still need participatory technology assessment?
por: Hennen, Leonhard
Publicado: (2012)

Do we still need renal biopsy in lupus nephritis?
por: Haładyj, Ewa, et al.
Publicado: (2016)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
por: Derosa, Giuseppe, et al.
Publicado: (2007)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Cryoballoon ablation: Do we still need real-time recordings?
por: Bisignani, Antonio, et al.
Publicado: (2021)

What do we still need to learn on digitally assessed biomarkers?
por: Acs, Balazs, et al.
Publicado: (2021)

Perspective Technologies of Vaccination: Do We Still Need Old Vaccines?
por: Isaguliants, Maria, et al.
Publicado: (2022)

Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
por: Liao, Hung-Wei, et al.
Publicado: (2017)

Opinion: PARP inhibitors in cancer—what do we still need to know?
por: Wicks, Andrew J., et al.
Publicado: (2022)

PRO: Do We Still Need Whole-Brain Irradiation for Brain Metastases?
por: Popp, Ilinca, et al.
Publicado: (2023)

Do we still need to talk about maternal morbidity and near miss?
por: Fonseca, Sandra Costa
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2kfkpeg4eh1pq7dn91ailpi7vp